智通财经APP讯，古兜控股(08308)发布公告，认购协议所载的所有先决条件均已达成，并于2025年8月 18日完成。占经发行及配发认购股份而扩大的公司已发行股本约8.79%的合共1.20亿股股份已成功按每 股认购价0.058港元发行予认购人。 ...

Core Viewpoint - The company has signed a significant sales agreement for green hydrogen production equipment, marking a milestone in the application of electrolysis technology in the industrial sector of Northwest China [1] Group 1: Sales Agreement Details - The company’s subsidiary, Xinjiang Guofu Mingzhi Hydrogen Energy Technology Co., Ltd., has entered into a sales agreement for 100 megawatts of green hydrogen production equipment valued at over RMB 150 million [1] - The agreement includes the supply of 22 sets of 1,000 standard cubic meters per hour electrolyzers, gas-liquid treatment equipment, green hydrogen control systems, safety detection systems, and auxiliary equipment [1] Group 2: Strategic Importance - This collaboration signifies a deep partnership with the customer, leveraging the abundant renewable energy resources in the Hami region, such as wind and solar power [1] - The agreement represents the company's first comprehensive green hydrogen metallurgy solution in the green metallurgy sector, aligning with the long-term strategic planning of integrating hydrogen energy with the metallurgy industry [1]

新京报贝壳财经讯 8月18日，美图公司公告，截至2025年6月30日止六个月，收入18.21亿元，同比增长 12.3%。经调整净利润4.67亿元，同比增长71.3%。月活跃用户达2.8亿，同比增长8.5%。付费订阅用户 数达约1540万，其中约1360万来自生活场景应用及180万来自生产力工具。 ...

凯升控股(00102.HK)发布公告，由于本公司未能于2025年7月10日前完全满足复牌指引及恢复公司股份 于联交所买卖，故于2025年8月15日，联交所上市委员会议决根据第6.01A(1)条取消公司的上市地位。 截至2025年8月18日收盘，凯升控股(00102.HK)报收于0.05港元，与上一交易日持平，成交量--股，成交 额0.0港元。投行对该股关注度不高，90天内无投行对其给出评级。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 | 指标 | 凯升控股 | 其他休闲服务 行业平均 | 行业排名 | | --- | --- | --- | --- | | ROE | | 5.62% | | | 港股流通市值 | 2.12亿 | 431.27亿 | 21 29 | | 营业收入 | | 258.62亿 | | | 净利率 | | -15.07% | | | 毛利率 | | 33.9% | | | 负债率 | | 91.95% | | 凯升控股港股市值2.12亿港元，在其他休闲服务行业中排名第21。主要指标见下表： ...

Core Viewpoint - Hansoh Pharmaceutical (03692.HK) demonstrated strong performance in its 2025 interim results, showcasing growth driven by innovation and global strategies, with revenue reaching approximately 7.434 billion RMB, a year-on-year increase of about 14.3% [1] Financial Performance - The company reported a profit of approximately 3.135 billion RMB, reflecting a year-on-year growth of about 15.0% [1] - Basic earnings per share were approximately 0.53 RMB, up by about 14.8% year-on-year, with an interim dividend of 0.2316 HKD per share [1] - Operating cash flow for the first half of 2025 was 3.605 billion RMB, with cash and bank deposits totaling 27.104 billion RMB as of June 30, 2025, indicating a solid financial position [1] Revenue Breakdown - Sales revenue from innovative drugs and collaborative products reached approximately 6.145 billion RMB, a year-on-year increase of about 22.1%, accounting for 82.7% of total revenue [1] - Revenue from specific therapeutic areas included approximately 4.531 billion RMB from oncology, 735 million RMB from anti-infection, 768 million RMB from central nervous system, and 1.4 billion RMB from metabolic and other diseases, representing 60.9%, 9.9%, 10.4%, and 18.8% of total revenue respectively [1] R&D Investment - R&D expenditure for the first half of 2025 was approximately 1.441 billion RMB, a year-on-year increase of 20.4%, constituting 19.4% of total revenue [2] - The company is advancing over 70 clinical trials across more than 40 innovative drug projects, with 8 new candidates entering clinical research in the first half of 2025 [2] Key Product Developments - In the first half of 2025, the company initiated 3 new Phase III pivotal registration clinical trials for innovative drugs targeting B7-H3 ADC for bone and soft tissue sarcoma, B7-H4 ADC for ovarian cancer, and an IL23p19 monoclonal antibody for moderate to severe plaque psoriasis [3] - The GLP-1/GIP dual receptor agonist HS-20094 is in Phase III clinical research for obesity or overweight, with over 1,000 subjects dosed [3] Strategic Partnerships - In June 2025, the company granted Regeneron global exclusive rights to the GLP-1/GIP dual receptor agonist HS-20094 (excluding mainland China, Hong Kong, and Macau), receiving an upfront payment of 80 million USD and potential milestone payments up to 1.93 billion USD, along with double-digit royalties on future product sales [4] - The company is actively pursuing global licensing opportunities to accelerate the commercialization of its innovative pipeline, enhancing the commercial value of its products [4]

智通财经 APP 获悉，作为生物偶联药物 CRDMO 领域龙头公司，药明合联(02268)于 8 月 18 日晚间发布了 2025年上半年业绩公告，再度以领跑行业的亮眼 业绩惊艳市场，2025年上半年，公司收入增长62.2%，远超全年增速指引。2022年上半年至2025年上半年，公司收入的年复合增长率(CAGR)高达98%。经过 多年的高速增长，公司市占率自2022年以来持续大幅攀升，2025年上半年达到约22%。这一系列惊人的数字不仅彰显了生物偶联药赛道持续强劲的发展动 能，更充分印证了药明合联在行业内的标杆地位不可撼动，引领势能锐不可挡。 01 药明合联上半年收入利润增幅引航CXO行业 药明合联的业绩表现堪称典范，向市场交出了一份"满分"答卷：公司2025年上半年营业收入达27.01亿元，同比增长62.2%，其中非ADC板块的业务收入更是 实现近翻倍增长；毛利润达9.75亿元，同比增长82.2%；毛利率攀升至36.1%，较2024年全年提升5.5个百分点；更能反应公司实际经营指标的剔除利息收支 后经调整净利润达7.33亿元，同比增长69.6%。各项核心指标均保持强劲增长态势，是ADC CRDMO领域当之无 ...

公告称，预期亏损净额主要归因于(1)展览及活动相关服务收入减少约人民币1400万元;及(2)一次性收回 2024年同期的贸易应收款项预期信贷亏损约人民币870万元，该收回为非经常性事项。来自展览及活动 相关服务的收入减少了两倍。于回顾期内，一名主要客户拟进行一个大型项目并要求提供不可持续的低 报价，经审慎考虑后，该集团决定不进行上述项目。此外，另一个主要客户在回顾期内启动供应商重新 招标流程，导致公司计划正式启动的合作推迟，进一步影响公司在回顾期的收入变现。 智通财经APP讯，天平道合(08403)公布，该集团预期于2025年上半年取得亏损净额约人民币1300万元， 而2024年同期则取得溢利约人民币450万元。 ...

公告称，收益增长主要归因于集团持续努力扩充产品来源以扩阔产品组合。 智通财经APP讯，京玖康疗(00648)发布2025年中期业绩，收益3577.1万港元，同比增加16.5%;股东应占 溢利335.3万港元，上年同期股东应占亏损609.3万港元，同比扭亏为盈;每股基本盈利1港仙。 ...

智通财经APP讯，天福(06868)发布公告，将于2025年9月29日派发中期股息每股0.02港元 ...

智通财经APP讯，中国宏桥(01378)发布公告，于2025年8月18日，根据由公司股东于2025年5月7日举行 的股东周年大会上授出的股份购回授权，公司已分别按每股股份的最高及最低价格23.24港元及22.10港 元购买公司1015.1万股普通股。就股份购回支付的总购买价(不包括佣金及其他支出)约为2.34亿港元。 ...